A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Dose Escalation, and Food-Effect Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of INCB000631 When Administered Orally to Healthy Adult Participants
Latest Information Update: 17 Jun 2025
At a glance
- Drugs INCB 000631 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Incyte Corporation
Most Recent Events
- 11 Jun 2025 Status changed from active, no longer recruiting to completed.
- 20 May 2025 Status changed from recruiting to active, no longer recruiting.
- 06 Feb 2025 Status changed from not yet recruiting to recruiting.